clinical trial · NCT07533175
AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
Novo Nordisk A/S·phase3·not yet recruiting·n = 630
Diabetes MellitusOverweightObesityNNC0487-0111Placebo (matched to NNC0487-0111)
brief summary
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and type 2 diabetes. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) or Placebo (treatment that has no active medicine in it). Which treatment participants get is decided by chance.
started
Apr 13, 2026
primary completion
May 15, 2028
completion
Aug 7, 2028
last updated
Apr 16, 2026
official title
Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Type 2 Diabetes (AMAZE 2)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol